Thoracic cancer · 2025
Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huan, Du Xingyu, Guan Song, Wang Hui, Xing Yan, Tian Cuimeng, Wen Li
Аннотация
OBJECTIVE: To compare the predictive value of the estimated dose of radiation to immune cells (EDRIC) with conventional dosimetric parameters for survival in elderly patients with stage III unresectable NSCLC after chemoimmunotherapy and radiotherapy.
METHODS: We conducted a retrospective study of elderly patients (≥ 65 years) treated at two institutions. Patients were stratified by median EDRIC, mean lung dose (MLD), mean heart dose (MHD), and mean body dose (MBD). Survival was analyzed using Kaplan-Meier, Cox regression, and ROC curves.
RESULTS: Baseline characteristics were well-balanced across dosimetric parameter subgroups (all p > 0.05). The median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 23.9 months and 46.0 months, respectively. EDRIC ≥ 6.4 Gy was associated with worse PFS (p = 0.019) and OS (p = 0.011), while MLD, MHD, and MBD showed no prognostic significance (all p > 0.05). Multivariate analysis identified EDRIC ≥ 6.4 Gy as an independent predictor of worse PFS (HR = 1.852, p = 0.049) and OS (HR = 2.289, p = 0.048). Age ≥ 70 years was also independently associated with poorer OS (HR = 2.870, p = 0.011). ROC analysis demonstrated superior predictive performance of EDRIC over conventional parameters for 1-, 2-, and 3-year PFS and OS, with particularly outstanding discrimination for 12-month OS (AUC = 0.93).
CONCLUSION: EDRIC shows potential in predicting survival for elderly stage III unresectable NSCLC patients, with 6.4 Gy as a potential threshold for personalized radiotherapy optimization. These findings require prospective validation.
METHODS: We conducted a retrospective study of elderly patients (≥ 65 years) treated at two institutions. Patients were stratified by median EDRIC, mean lung dose (MLD), mean heart dose (MHD), and mean body dose (MBD). Survival was analyzed using Kaplan-Meier, Cox regression, and ROC curves.
RESULTS: Baseline characteristics were well-balanced across dosimetric parameter subgroups (all p > 0.05). The median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 23.9 months and 46.0 months, respectively. EDRIC ≥ 6.4 Gy was associated with worse PFS (p = 0.019) and OS (p = 0.011), while MLD, MHD, and MBD showed no prognostic significance (all p > 0.05). Multivariate analysis identified EDRIC ≥ 6.4 Gy as an independent predictor of worse PFS (HR = 1.852, p = 0.049) and OS (HR = 2.289, p = 0.048). Age ≥ 70 years was also independently associated with poorer OS (HR = 2.870, p = 0.011). ROC analysis demonstrated superior predictive performance of EDRIC over conventional parameters for 1-, 2-, and 3-year PFS and OS, with particularly outstanding discrimination for 12-month OS (AUC = 0.93).
CONCLUSION: EDRIC shows potential in predicting survival for elderly stage III unresectable NSCLC patients, with 6.4 Gy as a potential threshold for personalized radiotherapy optimization. These findings require prospective validation.